Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

Published
14 hours ago
From
Poz
Curing HIV just got more complicated. Can CRISPR help?

Antiretroviral (ARV) drugs have turned HIV infection from a death sentence to a chronic condition. In most people the drugs routinely tamp HIV levels so low that standard tests find no virus in blood samples. But inexplicably, in about 10% of infected people HIV remains easily detectable in the blood even though they take their daily pills and are not saddled with drug-resistant mutants of the virus.

Published
18 March 2019
From
Science
South Africa: Shortage of drug puts thousands of Aids patients at risk

Health authorities have confirmed the shortage of Darunavir, a third-line drug. Third-line drugs are used when patients have few drug options left to treat their condition.

Published
15 March 2019
From
Independent Online
More than 1 year to HIV control raises failure risk almost 10-fold

Failure to reach an undetectable viral load in the first year of antiretroviral therapy (ART) led to nearly a 10-fold higher risk of subsequent virologic failure in a 17,000-person North American analysis [1]. Taking more than 1 year to control HIV did not confer a higher risk of low-level viremia or viral blips in this 6-year study.

Published
15 March 2019
From
NATAP
Up to 95% virologic response rate with rapid ART in safety-net clinic

Up to 95% of people with newly diagnosed HIV and beginning antiretroviral therapy (ART) within a week of diagnosis reached a viral load below 50 copies in the first year of therapy. High proportions of people in this San Francisco safety-net clinic had a substance use disorder, a major mental health diagnosis, or unstable housing.

Published
14 March 2019
From
NATAP
Inactive Ingredients in Medications Cause Trouble for Some

Most approved medications have inactive ingredients that could cause problems for individuals with allergies or intolerances to those ingredients, researchers say. Those problems can add up when patients take more than one medication with troublesome ingredients.

Published
14 March 2019
From
Medscape (requires free registration)
Italy's therapeutic AIDS vaccine shows drastic reduction of HIV virus reservoirs: study

Clinical trials of an Italian therapeutic vaccine against AIDS showed a drastic reduction of virus reservoirs in treated patients, Italian researchers said on Wednesday.

Published
14 March 2019
From
Xinhua
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
Large French study examines neuropsychiatric side effects with integrase inhibitors

The largest prospective study to date on integrase inhibitors and their potential for being associated with neuropsychiatric side effects was conducted in France. With more than 21,000 HIV-positive participants, the study found that the proportion of people who stopped taking integrase inhibitors due to neuropsychiatric side effects was generally very low (between 1% and 3%). Of particular note is the fact that before starting treatment with an integrase-inhibitor-containing regimen, between 3% and 10% of participants had previously reported neuropsychiatric side effects with other classes of HIV treatment.

Published
12 March 2019
From
CATIE
Can high-dose dolutegravir be a rescue therapy?

A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

Published
12 March 2019
From
CATIE
← First12345...204Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.